1. Home
  2. Analysis
  3. Clobazam
  4. Aromasin

Clobazam and Aromasin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Clobazam (clobazam) and Aromasin (exemestane). Common drug interactions include epilepsy among females.

The phase IV clinical study analyzes what interactions people have when they take Clobazam and Aromasin. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Clobazam?

Clobazam has active ingredients of clobazam. eHealthMe is studying from 14,399 Clobazam users. Check the latest studies of Clobazam.

What is Aromasin?

Aromasin has active ingredients of exemestane. It is often used in breast cancer. eHealthMe is studying from 12,863 Aromasin users. Check the latest studies of Aromasin.

On Jul, 18, 2026

17 people who take Clobazam and Aromasin together, and have interactions are studied.

Clobazam and Aromasin drug interactions.

What are the common drug interactions of Clobazam and Aromasin, by gender? *:

female:

  1. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
  2. Pneumonia
  3. Cataract (clouding of the lens inside the eye)

male:

n/a

What are the common drug interactions of Clobazam and Aromasin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
  2. Pneumonia
  3. Cataract (clouding of the lens inside the eye)

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Fainting (loss of consciousness and postural tone): 17 people, 100.00%
  2. Cataract (clouding of the lens inside the eye): 15 people, 88.24%
  3. Headache (pain in head): 4 people, 23.53%
  4. Spinal Pain (pain in spine): 3 people, 17.65%
  5. Pneumonia: 3 people, 17.65%
  6. Metastases To Bone (cancer spreads to bone): 3 people, 17.65%
  7. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Clobazam and Aromasin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Clobazam and Aromasin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Clobazam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Aromasin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Clobazam and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Aromasin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on clobazam and exemestane (the active ingredients of Clobazam and Aromasin, respectively), and Clobazam and Aromasin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.